NASDAQ:OABI

OmniAb (OABI) Stock Price, News & Analysis

OmniAb logo
$3.74 -0.08 (-1.97%)
As of 10:36 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About OmniAb Stock (NASDAQ:OABI)

Key Stats

Today's Range
$3.73
$3.85
50-Day Range
$3.17
$4.06
52-Week Range
$3.10
$6.55
Volume
78,979 shs
Average Volume
479,999 shs
Market Capitalization
$527.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00
Consensus Rating
Buy

Company Overview

OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.

OmniAb Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
34th Percentile Overall Score

OABI MarketRank™: 

OmniAb scored higher than 34% of companies evaluated by MarketBeat, and ranked 787th out of 959 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    OmniAb has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    OmniAb has received no research coverage in the past 90 days.

  • Read more about OmniAb's stock forecast and price target.
  • Earnings Growth

    Earnings for OmniAb are expected to grow in the coming year, from ($0.61) to ($0.46) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of OmniAb is -6.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of OmniAb is -6.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    OmniAb has a P/B Ratio of 1.42. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about OmniAb's valuation and earnings.
  • Percentage of Shares Shorted

    8.08% of the float of OmniAb has been sold short.
  • Short Interest Ratio / Days to Cover

    OmniAb has a short interest ratio ("days to cover") of 15.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in OmniAb has recently increased by 1.54%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    OmniAb does not currently pay a dividend.

  • Dividend Growth

    OmniAb does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.08% of the float of OmniAb has been sold short.
  • Short Interest Ratio / Days to Cover

    OmniAb has a short interest ratio ("days to cover") of 15.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in OmniAb has recently increased by 1.54%, indicating that investor sentiment is decreasing.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for OmniAb this week, compared to 2 articles on an average week.
  • MarketBeat Follows

    5 people have added OmniAb to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, OmniAb insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $268,356.00 in company stock.

  • Percentage Held by Insiders

    Only 8.60% of the stock of OmniAb is held by insiders.

  • Percentage Held by Institutions

    72.08% of the stock of OmniAb is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about OmniAb's insider trading history.
Receive OABI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OmniAb and its competitors with MarketBeat's FREE daily newsletter.

OABI Stock News Headlines

OmniAb, Inc. (NASDAQ:OABI) CFO Sells $50,304.24 in Stock
OmniAb (OABI) Gets a Buy from RBC Capital
Forget morning trades: Here’s when real money moves
When 12pm Eastern rolls around… Something really special happens. It’s the first hour of the day that the overseas markets are closed… And it’s the FIRST time that we can see Wall Street trading freely on their own – without the noise from the international markets… That’s why we see so many opportunities during the Genesis Hour. And anyone who can spot stocks breaking out during the 12 pm Genesis Hour can then jump in ahead of what could be the next big move… Intrigued? You should be! Because it’s one of the most exciting, little-known revelations I’ve uncovered in my 40+ years trading the markets. If you’d like to join him for a deeper dive…
OmniAb Insider Ups Holding During Year
See More Headlines

OABI Stock Analysis - Frequently Asked Questions

OmniAb's stock was trading at $3.54 on January 1st, 2025. Since then, OABI shares have increased by 7.6% and is now trading at $3.81.
View the best growth stocks for 2025 here
.

OmniAb, Inc. (NASDAQ:OABI) released its quarterly earnings results on Thursday, August, 8th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.05. The business earned $7.61 million during the quarter, compared to analysts' expectations of $6.52 million. OmniAb had a negative trailing twelve-month return on equity of 20.97% and a negative net margin of 308.78%.

OmniAb's top institutional investors include Janus Henderson Group PLC (5.64%), Vanguard Group Inc. (3.58%), Dimensional Fund Advisors LP (2.14%) and Chicago Capital LLC (2.11%). Insiders that own company stock include Charles S Berkman, Kurt A Gustafson and Jennifer R Cochran.
View institutional ownership trends
.

Shares of OABI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that OmniAb investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Arista Networks (ANET), Advanced Micro Devices (AMD), CrowdStrike (CRWD) and Adobe (ADBE).

Company Calendar

Last Earnings
8/08/2024
Today
2/18/2025
Next Earnings (Estimated)
5/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Commercial physical research
Sub-Industry
Business Services
Current Symbol
NASDAQ:OABI
Fax
N/A
Employees
7
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.00
High Stock Price Target
$11.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+136.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-50,620,000.00
Net Margins
-308.78%
Pretax Margin
-373.44%

Debt

Sales & Book Value

Annual Sales
$34.16 million
Book Value
$2.69 per share

Miscellaneous

Free Float
129,071,000
Market Cap
$538.05 million
Optionable
Optionable
Beta
-0.12
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (NASDAQ:OABI) was last updated on 2/18/2025 by MarketBeat.com Staff
From Our Partners